Core Insights - The Social Security Administration announced a 2.8% cost-of-living adjustment (COLA) for 2026, following a 2.5% increase in 2025, impacting 71 million Americans [1][2] - Dividend growth stocks have historically provided higher annual increases compared to Social Security adjustments, with several blue-chip companies consistently outperforming these adjustments [1][2] Dividend Growth Companies - **Caterpillar**: Achieved a 10-year compound annual dividend growth rate of 7.2%, with a quarterly dividend increase of 7.1% to $1.51 in December 2025, marking 32 consecutive years of increases [3][4] - **Coca-Cola**: Raised its dividend for 62 consecutive years, with a 10-year compound annual growth rate of 4.5% and a quarterly dividend increase of 5.2% to $0.51 in 2025 [6][8] - **Johnson & Johnson**: Also increased its dividend for 62 consecutive years, with a 10-year compound annual growth rate of approximately 6.5% and a quarterly dividend increase of 4.8% to $1.30 in 2025 [9][10] - **PepsiCo**: Maintained a 52-year dividend increase streak, with a 10-year compound annual growth rate of 7.1% and a quarterly dividend increase to $1.4225 in 2025 [12][14] - **Procter & Gamble**: Holds the longest streak with 68 consecutive years of dividend increases, averaging annual growth of 5-7% [15][17] Financial Performance - **Caterpillar**: Projected annual dividend increase from $1.84 in 2012 to $6.04 in 2026, a 228% increase over 14 years, with Q3 2025 operating cash flow of $3.7 billion [4][5] - **Coca-Cola**: Quarterly dividend increased from $0.16 in 1999 to $0.51 in 2025, a 219% increase, with Q3 2025 dividends totaling $2.108 billion [7][8] - **Johnson & Johnson**: Quarterly dividend increased from $0.25 in 1999 to $1.30 in 2025, a 420% increase, with Q3 2025 dividends of $3.132 billion [10][11] - **PepsiCo**: Annual dividend growth from $2.15 in 2012 to $5.55 in 2025, a 158% increase, with Q3 2025 dividends of $1.949 billion [13][14] - **Procter & Gamble**: Paid $2.549 billion in dividends in Q1 2026, with a current dividend yield of 2.93% and a 60% payout ratio [16][17]

A Los Angeles jury has awarded $40 million to two women who claim Johnson & Johnson's talcum powder caused their ovarian cancerA Los Angeles jury awarded $40 million on Friday to two women who claimed that talcum powder made by Johnson & Johnson caused their ovarian cancer.The giant health care company said it would appeal the jury's liability verdict and compensatory damages.The verdict is the latest development in a longstanding legal battle over claims that talc in Johnson's Baby Powder and Shower to Sho ...

Core Insights - The "High Income DIY Portfolios" service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees [1][2] - The service offers a total of 10 model portfolios, including various strategies like buy-and-hold and rotational portfolios, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1: Portfolio Strategies - The service includes seven portfolios: three buy-and-hold, three rotational, and a conservative NPP strategy portfolio, focusing on low drawdowns and high growth [1] - The portfolios are categorized into two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy [1] Group 2: Investment Approach - The investment approach emphasizes a unique 3-basket strategy that targets 30% lower drawdowns and aims for a 6% current income with market-beating growth over the long term [2] - The service provides buy and sell alerts, as well as live chat for real-time support and guidance [2]

北京市贸促会党组书记、北京国际商会会长章建伟指出，举办"京品出海"系列活动的核心是为企业搭建 精准高效的对接平台，切实助力企业开拓海外市场。专委会将紧密围绕企业实际需求，成为连接政府与 市场、国内与国际的重要桥梁。 据介绍，目前副中心已被纳入全市医药健康产业"多点"优势布局，漷县镇集聚区已吸引包括4家上市企 业在内的众多创新主体落户，预计今年产值达60亿元，明年目标突破百亿元。 新京报讯(记者陈琳)近日，由北京市贸促会、北京国际商会主办的"京品出海"医药健康行业专场分享会 举办。会上，北京国际商会医药健康专业委员会正式揭牌成立，标志着北京在推动医药健康产业国际化 方面迈出关键一步。活动吸引了来自全球多地的专业机构代表及150余家国内外企业参会。 在当前全球科技革命与产业变革加速的背景下，医药健康产业已成为创新最活跃的赛道之一。推动"京 品"医药健康产品与服务开拓国际市场，是企业提升竞争力的必然选择。新成立的医药健康专业委员会 由北京医药行业协会倡议发起，联合默沙东、赛诺菲、阿斯利康、强生等25家国内外知名企业共同组 成，旨在聚焦行业国际化发展的共性需求，提供政策解读、市场对接、合规指导等全链条服务。 ...

Core Points - A California jury awarded $40 million to two women who claimed Johnson & Johnson's baby powder caused their ovarian cancer, with $18 million to Monica Kent and $22 million to Deborah Schultz and her husband [1] - Johnson & Johnson plans to appeal the verdict, asserting confidence in overturning what they consider an aberrant decision [2] - The plaintiffs used J&J's baby powder for 40 years, with both women undergoing significant medical treatments for their cancer diagnoses [3] Company Knowledge and Response - The attorney for the plaintiffs argued that Johnson & Johnson was aware of the cancer risks associated with their product since the 1960s and attempted to conceal this information [4] - Johnson & Johnson's attorney countered that there is no substantial evidence linking talc to cancer, claiming that the connection was suggested by the plaintiffs' lawyers rather than supported by health authorities [5] Legal Context - Johnson & Johnson is facing over 67,000 lawsuits related to cancer claims from its talc products, maintaining that their products are safe and free from asbestos [6] - The company has attempted to resolve litigation through bankruptcy, but these attempts have been rejected by federal courts, leading to the current trial being the first since the latest bankruptcy effort was dismissed [7] Historical Legal Outcomes - Prior to the bankruptcy attempts, Johnson & Johnson had a mixed record in talc-related trials, with some verdicts reaching as high as $4.69 billion awarded to plaintiffs [8] - Most lawsuits focus on ovarian cancer claims, while a smaller number involve mesothelioma, with some cases proceeding to trial despite previous settlements [9] - In the past year, Johnson & Johnson has faced significant verdicts in mesothelioma cases, including a notable $900 million verdict in Los Angeles [10]

Core Points - A Los Angeles Superior Court jury awarded $40 million in compensatory damages against Johnson & Johnson [1] - The case involved two California women who developed ovarian cancer after long-term use of the company's talc-based baby powder products [1] - The trial lasted four weeks and included testimony from former United States officials [1]

Core Points - A California jury awarded $40 million to two women claiming that Johnson & Johnson's baby powder caused their ovarian cancer [1] Company Summary - Johnson & Johnson faces legal challenges related to its baby powder product, with significant financial implications following the jury's decision [1]

Core Insights - The FDA has approved AKEEGA, a dual-action tablet combining niraparib and abiraterone acetate, plus prednisone for treating patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), marking it as the first precision medicine combination treatment for this patient group [1][11][5] Group 1: Clinical Study and Efficacy - The approval is based on positive results from the AMPLITUDE study, which demonstrated that AKEEGA plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54% compared to the current standard of care [3][7] - AKEEGA plus prednisone and ADT also significantly prolonged the time to symptomatic progression by 59% [3][7] - The AMPLITUDE study enrolled 696 participants from 32 countries, focusing on patients with deleterious germline or somatic homologous recombination repair gene alterations [9] Group 2: Unmet Medical Need - Patients with BRCA2 mutations experience faster disease progression and shorter survival compared to those without the mutation, highlighting a significant unmet medical need [2][10] - Approximately 25% of patients with mCSPC have homologous recombination repair gene alterations, including BRCA mutations, which negatively impact outcomes [10] Group 3: Safety Profile - The safety profile of AKEEGA plus prednisone was consistent with the known safety profiles of each monotherapy, with common adverse reactions including decreased hemoglobin, musculoskeletal pain, and fatigue [4][39] - Serious adverse reactions occurred in 36% of patients treated with AKEEGA, with fatal adverse reactions reported in 4.9% of patients [38][39] Group 4: Company Commitment and Support - Johnson & Johnson emphasizes its commitment to providing personalized and effective treatment options for prostate cancer, supported by strong clinical data [5] - The company offers a patient support program, J&J withMe, to assist patients in accessing treatments and providing educational resources at no cost [6]

Key Points A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year despite some significant headwinds. The drugmaker is well equipped to deal with these challenges over the long term. 10 stocks we like better than Johnson & Johnson › Pharmaceutical giant Johnson & Johnson (NYSE: JNJ) has performed well this year. The company's shares are up by 45% since January. However, many investors, including institutio ...

Core Insights - The article emphasizes the importance of dividend investing, highlighting that the best dividend stocks not only provide consistent payouts but also increase their dividends over time, benefiting long-term shareholders [1] Group 1: Dividend Growth Leaders - Johnson & Johnson (JNJ) has a 2.54% yield and has increased dividends for 62 consecutive years, supported by a diversified portfolio in healthcare [5][6] - Coca-Cola (KO) boasts a 2.87% yield with 63 years of dividend increases, demonstrating strong operational performance and pricing power [8][9] - Procter & Gamble (PG) leads with 68 consecutive years of dividend increases, offering a 2.96% yield and showcasing operational excellence [11][12] - AbbVie (ABBV) has the fastest dividend growth in this ranking, with a recent 5.5% increase, bringing its yield to 2.94% [15][16] - Realty Income (O) offers a unique monthly dividend structure with a 5.62% yield, supported by a strong rent recapture rate and a long history of dividend increases [18][19] Group 2: Financial Performance - JNJ reported Q3 2025 EPS of $2.80, with revenue of $24.0 billion, and raised its full-year guidance, indicating confidence in growth [6][7] - Coca-Cola's Q3 2025 EPS was $0.86, with revenue of $12.5 billion and a stable operating margin of 32%, reflecting its ability to pass costs to consumers [9][10] - Procter & Gamble's Q1 fiscal 2026 EPS was $1.95, with revenue of $22.4 billion and a free cash flow of $5.4 billion, indicating strong cash generation [12][13] - AbbVie's Q3 2025 EPS was $1.86, with revenue of $15.8 billion, and management raised its EPS guidance for the full year [16][17] - Realty Income's Q3 2025 AFFO reached $1.08 per share, with a full-year guidance increase and a quarterly revenue growth of 10.3% year-over-year [19][20]